Answers are grounded in this paper and cite their sources.
Review highlights variable cancer risks linked to SGLT2 inhibitors, suggesting drug-immune interactions require critical evaluation.
Background.After their introduction to clinical use, several reports related the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to certain cancer.In this review, we will discuss whether the use SGLT2 inhibitors can increase cancer or, surprisingly, reduce the risk of certain cancers.We will also discuss the proposed mechanisms of inducing or inhibiting cancer by SGLT2 inhibitors with special attention to immunity as a point that needs further consideration.Summary.While some SLGT2 inhibitors might induce cancer in human, others might protect against cancer.Animal results showed some contradiction.None of the clinical studies considered the effect of SLGT2 inhibitors on immunity during assessment of the relationship between SLGT2 inhibitors and cancer.Key messages.It seems that the relationship between SLGT2 inhibitors and cancer is not a class.Further studies should focus whether the interaction between SLGT2 inhibitors and immune system could affect cancer growth.
No takes yet. Share an insight, caveat, or question.
Mohamed Abouelkheir (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: